Hormone Replacement Therapy is likely to influence metabolic risk factors and could affect the risk of coronary heart disease and stroke.
Does Hormone Replacement Therapy impact cardiometabolic risk factors, coronary heart disease, stroke, and MASLD in menopausal women?
This narrative review highlights the complex impact of HRT on cardiometabolic risk factors, coronary heart disease, stroke, and MASLD, emphasizing the need for further research on route, timing, and formulation.
Absolute Event Rate: 0% vs 0%
Existing evidence suggests that HRT is likely to impact the development of metabolic risk factors including visceral fat accumulation, adverse changes in lipid profile, blood pressure and glycaemic control. Findings from randomised controlled trials have refined our understanding of the impact of HRT on cardiometabolic outcomes including coronary heart disease and stroke. Furthermore, recent research has highlighted the impact of the menopause on the development and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) that has been poorly studied in the context of HRT. The route of oestrogen administration, timing of initiation and type of progestogen are all likely to affect the impact of HRT on many of these outcomes. There has recently been extensive media interest in HRT in some countries resulting in increased prescription rates. Understanding the impact of HRT on cardiometabolic risk is therefore particularly important. In this narrative review, we discuss the existing evidence and clinical guidelines on the effect of HRT on cardiometabolic risk factors and the risk of coronary heart disease, stroke and MASLD, highlighting areas of uncertainty and priorities for further research.
Dong et al. (Wed,) reported a other. Hormone Replacement Therapy is likely to influence metabolic risk factors and could affect the risk of coronary heart disease and stroke.